AstraZeneca's Tagrisso Price Tag Is 'Clearly A Strategy'
AstraZeneca PLC has priced its newly approved lung cancer therapy at a "competitive" rate, at $12,750 (£8,944) per patient per month, keeping its eyes on a future first-line use indication.
AstraZeneca PLC has priced its newly approved lung cancer therapy at a "competitive" rate, at $12,750 (£8,944) per patient per month, keeping its eyes on a future first-line use indication.